Max-3 is under clinical development by Maxinovel Pharmaceuticals and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Max-3 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Max-3 is under development for the treatment of alopecia areata and atopic dermatitis. The drug candidate is administered by the topical route. It acts by targeting Janus kinase (JAK) and non-receptor tyrosine-protein kinase (TYK2).
Maxinovel Pharmaceuticals overview
Maxinovel Pharmaceuticals is a biotechnology company that specializes in disease areas characterized by high mortality and high morbidity with no effective treatment. The company is headquartered in China.
For a complete picture of Max-3’s drug-specific PTSR and LoA scores, buy the report here.